The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Despite there being a valid 'cspec' property in the messages there's a discrepancy in message contents and CSPEC data: * Message Gene: MT-CO1 CSPEC Genes: [] * Message MONDOs: MONDO:0044970 CSPEC MONDO: []
  • No CSPEC computed assertion could be determined for this classification!


Variant: NC_012920.1:m.7443A>G

CA347798

40158 (ClinVar)

Gene: MT-CO1
Condition: mitochondrial disease
Inheritance Mode: Mitochondrial inheritance
UUID: 90cab362-378c-4d46-b6d3-5ad3760fc316
Approved on: 2024-07-08
Published on: 2024-12-09

HGVS expressions

NC_012920.1:m.7443A>G
J01415.2:m.7443A>G
ENST00000361624.2:c.1540A>G

Uncertain Significance

Met criteria codes 2
PM2_Supporting PS3_Supporting
Not Met criteria codes 2
PS4 PP3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Mitochondrial Disease Nuclear and Mitochondrial Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1_mtDNA

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Mitochondrial Diseases VCEP
The m.7443A>G (p.*514G) variant in MT-CO1 has been reported in one individual with primary mitochondrial disease to date (PMID: 10577941), in a child enrolled at the School for Deaf and Blind in Mongolia. He was reported to have been deaf since infancy. The variant appeared to be homoplasmic. Information was not provided on the family history of this individual. There are no additional case reports to our knowledge. There are several occurrences of this variant in population databases (Mitomap: 1/61,134, gnomAD: 1/56,434, Helix: 4/195,893). Although there are several occurrences, the frequency is still low (PM2_supporting). There are no in-silico prediction tools for a stop-loss variant in mitochondrial DNA, although this variant would not be expected to cause run-through due to the excision of the tRNA immediately adjacent. Functional studies showed inefficient processing (29% of wild type) by tRNAseZ in the presence of this variant (PS3_supporting; PMID: 16361254). In summary, this variant meets criteria to be classified as uncertain significance for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on July 8, 2024. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PS3_supporting, PM2_supporting.
Met criteria codes
PM2_Supporting
There are several occurrences in population databases (Mitomap: 1/61,134, gnomAD: 1/56,434, Helix: 4/195,893). Although there are several occurrences, the frequency is still low (PM2_supporting).
PS3_Supporting
Yan et al 2006 (PMID 16361254) demonstrated inefficient processing (29% of WT) by tRNAseZ in the presence of this mutation.
Not Met criteria codes
PS4
The MT-CO1 m.7443A>G (*514G) variant was reported in one student of ~400 from the School for Deaf and Blind in Mongolia. He was reported to have been deaf since infancy (Pandya et al 1999, PMID 10577941). The variant appeared to be homoplasmic by Sequenase PCR sequencing. Both m.1555A>G and m.7445A>G were absent. No family information was reported for this patient and no other mitochondrial disease cases were found with m.7443A>G in our review of the literature.
PP3
There are no in-silico prediction tools for a stop-loss variant in mitochondrial DNA, although this variant would not be expected to cause run-through due to the excision of the tRNA immediately adjacent.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.